Adjuvant therapy of uterine clear cell carcinoma: a review

Xu, Yiqing; Hanna, Rabbie K.; Elshaikh, Mohamed A.

doi:10.1007/s00404-015-3973-x

Cited by 11 publications

(10 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, adjuvant RT has been applied for the treatment of early stage UCCC, a rationale inferred from the outcome data for women with uterine serous carcinoma and grade III endometrioid carcinoma (20). Lastly, Kim et al conducted a large retrospective analysis of 451 UCCC and 882 UPSC (uterine papillary serous carcinoma) patients from the SEER database and found that the 5-year OS for RT and non-RT patients at stage IB were 76% and 66% respectively (p = 0.006) whereas the 5-year OS for RT and non-RT patients at stage IC were 60.7% and 33.9% respectively (p = 0.001) (23).…”

Section: In the Latest Randomized Trial Of Radiation Therapy With Or mentioning

confidence: 99%

WITHDRAWN: Outcomes in patients with early stage uterine clear cell carcinoma treated with chemotherapy and radiotherapy: A systematic review and meta-analysis

Yin

Cheng

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background : Uterine clear cell carcinoma (UCCC) is a rare histological type of endometrial cancer with poor prognosis and high risk of tumor relapse. Although adjuvant chemotherapy (CT) and/or radiotherapy (RT) are often recommended for early stage UCCC patients, the effectiveness of these treatment strategies remains unclear. Methods : Systematic review and meta-analysis were applied to evaluate treatment-related outcomes of stage I-II UCCC patients. Search strategy was applied using electronic databases until June 1st, 2019. Inclusion criteria were retrospective, observational and prospective studies that reported outcome of UCCC patients receiving adjuvant therapy. Clinical endpoints like overall survival (OS) and progression-free survival (PFS) were evaluated. Data were extracted by two independent reviewers and a meta-analysis was performed. Results : 13 articles with a total of 3967 patients were analyzed. Overall, adjuvant CT after surgery could improve 5 year-OS significantly compared to patients without CT (odds ratio 0.75, 95% confidence interval [CI] 0.58-0.96; p=0.02). In comparison, RT could also improve OS in UCCC patients of early stage (odds ratio 0.58, 95% CI 0.44-0.77; p=0.0002) compared to the patients without RT, especially in US and Europe patients. Lastly, when comparing the patients undergoing both CT and RT with those receiving CT or RT alone, no further improvement in OS was observed (odds ratio 1.12, 95% CI 0.63-1.99; P=0.70). Conclusions : Either CT or RT after surgery could improve the OS of early stage of UCCC patients. However, combinatorial CT and RT treatment did not improve the OS compared with CT or RT treatment alone.

show abstract

Section: In the Latest Randomized Trial Of Radiation Therapy With Or mentioning

confidence: 99%

WITHDRAWN: Outcomes in patients with early stage uterine clear cell carcinoma treated with chemotherapy and radiotherapy: A systematic review and meta-analysis

Yin

Cheng

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Foretinib treatment had significant effects in all of our in vivo experiments, and the most notable finding was that it led to the complete disappearance of the TEN cell tumor xenografts. This finding could be important for patients with uterine clear cell carcinoma because clear cell carcinoma is known to have a poor prognosis due to the high rate of drug resistance [ 27 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer

et al. 2018

View full text Add to dashboard Cite

ObjectiveForetinib (GSK1363089 or XL880), which is an oral multikinase inhibitor developed to primarily target the hepatocyte growth factor (HGF)/Met signaling pathway, has shown anti-tumor effects against some cancers in preclinical and clinical studies.ResultsHGF/Met signaling in endometrial cancer cell lines was stimulated in an autocrine manner, and was essential for cell survival. Inhibiting the HGF/Met signaling with foretinib induced p53-dependent apoptosis in endometrial cancer cell lines in vitro. Foretinib also showed significant anti-cancer effects in vivo in experiments using cell tumor xenografts. p53 mutations were observed in 37 (10.8%) of 344 endometrial cancer specimens.ConclusionThe HGF/Met-MAPK/PI3K pathway in endometrial cancer is activated by HGF in an autocrine manner. Foretinib induces an anti-cancer effect through the anti-phosphorylation of Met, which results in the induction of p53-dependent apoptosis; foretinib was found to exert greater anti-cancer activity in endometrial cancer specimens with wild-type p53 than in specimens with p53 mutations. Our immunochemical analysis revealed that foretinib-induced p53-dependent apoptosis can be expected to have therapeutic potential in approximately 90% of endometrial cancer patients.MethodsWe evaluated the HGF/Met signaling pathway in endometrial cancer cell lines and assessed the anti-cancer effects of foretinib using in vitro and in vivo experimental models. Furthermore, endometrial cancer specimens were subjected to an immunohistochemical analysis.

show abstract

“…Compared with endometrioid carcinoma (EC), patients with CCC have a worse prognosis ( 5 ). The 5-year overall survival rate of patients with higher International Federation of Gynecology and Obstetrics (FIGO) stage is below 50% ( 6 ).…”

Section: Introductionmentioning

confidence: 99%

Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in 27 Cases

et al. 2021

View full text Add to dashboard Cite

ObjectiveClear cell carcinoma (CCC) of the endometrium is an uncommon yet aggressive tumor. Few cohort studies are reporting the overall survival time of CCC patients. This study aimed to retrospectively analyze the clinicopathologic features, molecular characteristics and survival data of 27 endometrial CCC patients to improve the understanding of CCC.MethodsThe clinicopathologic features, molecular characteristics and survival data total of 27 CCC patients admitted to the BBMU affiliated hospital (Anhui, China) between January 2005 and December 2018 were retrospectively analyzed. Kaplan-Meier method was used to analyze the prognosis-related factors.ResultsThe median age of the patients was 60 years (range; 39 to 81 years). The average tumor size was 3.8 cm (range; 0.8 to 13.0cm). Myometrial infiltration greater than 50% was reported in 55.6% of the patients, while the Ki-67 index greater than 50% was reported in 70.4% of the patients. The patients’ FIGO (2009) surgical stages were as follows: 18 I, 3 II, 4 III, and 2 IV. Besides, 7 (25.6%) patients had lymphovascular invasion, 3 (11.1%) patients with distant metastasis, including 1 patient with bone metastasis, and 2 with liver metastasis. Adjuvant treatment included 7 with chemotherapy alone, 9 with radiotherapy alone, and 9 with both radiotherapy and chemotherapy. The median overall survival time from the time of CCC diagnosis was 56 months. ER and PR showed negative expression and P16 showed patchy immunostaining. 18 (63%) cases showed Napsin A positive expression. Loss of MSH2, MSH6 and PTEN were seen in 5, 4 and 7 cases respectively. All cases showed HER-2/nue negative expression.ConclusionCCC is a rare and invasive tumor. Age of diagnosis, FIGO stage, tumor size, myometrial infiltration, lymphovascular invasion, distant metastasis, Ki-67 index and P53 expression are important indicators to evaluate patient’s prognosis (P = 0.048, P < 0.001, P = 0.016, P = 0.043, P = 0.001, P < 0.001, P = 0.026, and P = 0.007, respectively). CCC has a worse prognosis than endometrioid carcinoma (P = 0.002), and there is no significant difference when compared with uterine papillary serous carcinoma (P = 0.155).

show abstract

Adjuvant therapy of uterine clear cell carcinoma: a review

Cited by 11 publications

References 51 publications

WITHDRAWN: Outcomes in patients with early stage uterine clear cell carcinoma treated with chemotherapy and radiotherapy: A systematic review and meta-analysis

WITHDRAWN: Outcomes in patients with early stage uterine clear cell carcinoma treated with chemotherapy and radiotherapy: A systematic review and meta-analysis

Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer

Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in 27 Cases

Contact Info

Product

Resources

About